Strs Ohio Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Strs Ohio lifted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 758.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,300 shares of the biotechnology company’s stock after buying an additional 9,100 shares during the period. Strs Ohio’s holdings in Arrowhead Pharmaceuticals were worth $355,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth about $34,000. Salomon & Ludwin LLC purchased a new position in Arrowhead Pharmaceuticals in the third quarter valued at approximately $34,000. Nisa Investment Advisors LLC lifted its position in Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,308 shares in the last quarter. Daiwa Securities Group Inc. raised its position in Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 3,763 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Arrowhead Pharmaceuticals by 29.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 1,214 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Up 0.3%

Shares of ARWR opened at $69.33 on Monday. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $76.76. The business’s 50-day moving average price is $65.21 and its 200 day moving average price is $41.99. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $9.71 billion, a P/E ratio of -866.52 and a beta of 1.21.

Analysts Set New Price Targets

Several research firms recently commented on ARWR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, January 21st. Chardan Capital upped their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. B. Riley upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Finally, HC Wainwright increased their price target on Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $81.67.

Insiders Place Their Bets

In related news, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the transaction, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, December 15th. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the sale, the chief executive officer directly owned 3,971,255 shares of the company’s stock, valued at $273,420,906.75. This trade represents a 3.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 510,836 shares of company stock worth $33,603,060. Insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.